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We developed streamlined, automated puriﬁcation protocols for the production of milligram quantities
of untagged recombinant human cyclophilin-A (hCypA) and untagged human proliferating cell nuclear
antigen (hPCNA) from Escherichia coli, using the ÄKTAxpress™ chromatography system. The automated
2-step (cation exchange and size exclusion) puriﬁcation protocol for untagged hCypA results in ﬁnal
purity and yields of P93% and 5 mg L1 of original cell culture, respectively, in under 12 h, including
all primary sample processing and column equilibration steps. The novel automated 4-step (anion
exchange, desalt, heparin-afﬁnity and size exclusion, in linear sequence) puriﬁcation protocol for
untagged hPCNA results in ﬁnal purity and yields ofP87% and 4 mg L1 of original cell culture, respec-
tively, in under 24 h, including all primary sample processing and column equilibration steps. This saves
in excess of four full working days when compared to the traditional protocol, producing protein with
similar ﬁnal yield, purity and activity. Furthermore, it limits a time-dependent protein aggregation, a
problem with the traditional protocol that results in a loss of ﬁnal yield. Both automated protocols were
developed to use generic commercially available pre-packed columns and automatically prepared mini-
mal buffers, designed to eliminate user and system variations, maximize run reproducibility, standardize
yield and purity between batches, increase throughput and reduce user input to a minimum. Both pro-
tocols represent robust generic methods for the automated production of untagged hCypA and hPCNA.
 2009 Elsevier Inc. Open access under CC BY license. Introduction
The demand placed on protein production strategies, in terms of
the amount and purity of the protein products produced and the
need to develop reliable and robust generic puriﬁcation protocols,
has increased massively in the post genome-sequencing era [1].
This is especially so for the increasing pace and scope of structural
genomics and drug discovery programs, where there is very often a
need to generate tens of milligrams of highly pure protein on a reg-
ular basis, with as little batch variation as possible [1–5]. Modern
liquid chromatography instruments have become increasingly
automated [6–8] and associated separation media increasingly
sophisticated [9,10], resulting in the development of effective
methodologies for preparative protein puriﬁcation, with increased
throughput, becoming more and more routine [1]. However, more
often than not, these protocols are developed as bespoke methods
for a particular protein or family of proteins, and make use of some
very speciﬁc differences in biophysical properties particular to theear).
 license. individual protein(s). Although extremely effective, these bespoke
methods do not translate particularly well into generic or high-
throughput puriﬁcation strategies. In addition to this, the vast
majority of puriﬁcation strategies involve more than one step
(even for protocols utilizing some form of afﬁnity enrichment as
the ﬁrst step [11]) and most lab-scale chromatography instrumen-
tation normally only handles a single chromatographic step at a
time. As such, multistep puriﬁcation protocols frequently involve
time-consuming manual processing, including, for example, SDS–
PAGE analysis of chromatograms and the subsequent pooling of
the appropriate fractions, desalting or dialysis, concentration and
application of the partially processed sample to the next chroma-
tography column/step.
The ÄKTAxpress™ liquid chromatography system (GE Health-
care) was the ﬁrst widely available lab-scale system designed to
speciﬁcally help address these demands, allowing preparative mil-
ligram-level protein puriﬁcation protocols of up to 4-steps to be
automated and parallelized [6]. A peak detection algorithm and a
set of internal capillary loops allow peak fractions from intermedi-
ate steps to be collected automatically and processed through sub-
sequent chromatography steps in the protocol. The system is able
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change, desalt and gel-ﬁltration chromatography applications,
using a set of generic pre-packed column types, with the option
to include an on-column afﬁnity tag removal cleavage step, as part
of the protocol [6]. One major advantage of this system is the non-
modular design (apart from the columns and an external loop for
the application of a protease, no other components are removed
or added), which means each instrument is essentially operation-
ally identical. All instruments have the same ﬂow path delay vol-
umes, the same gradient delay volumes, the same set of pre-
deﬁned column types and the same sets of limited user-editable
protocol design parameters. This, in theory, means that there is
no appreciable difference in way the instruments are run between
laboratories, and translation of an already developed puriﬁcation
protocol from one instrument to another will not require any fur-
ther system/user speciﬁc optimization that often plagues research-
ers trying to replicate a method using a different chromatography
system to that used in a published protocol.
The vast majority of protocols using the ÄKTAxpress™ utilize
afﬁnity chromatography as the ﬁrst step [6,12], as this enrichment
technique is easily scaled to ﬁt the loop volume and sample han-
dling restrictions of the instrument (the standard conﬁguration
has ﬁve 10 ml loops with a nominal 7.5 ml collection and process
volume) for subsequent desalt or gel-ﬁltration steps in the proto-
col. However, the presence of an afﬁnity tag and optimizing its sub-
sequent removal (very often a requirement for structural work)
sometimes causes as many problems as the development of the
puriﬁcation protocol itself (even when utilizing the very widely
exploited poly-histidine tag [11]). The small size and highly
charged/polar nature of poly-histidine tags usually ensures that
tagged-proteins structure and activity is rarely affected, but there
are instances of this not being the case [13,14]. Two proteins of
particular interest to us as potential therapeutic targets – human
cyclophilin-A (hCypA)1 and human proliferating cell nuclear anti-
gen (hPCNA) – have exhibited problems as tagged-proteins.
Cyclophilins, found in all prokaryotes and eukaryotes and in all
cellular compartments, are involved in protein assembly and cellu-
lar signaling [15,16]. Their cellular function requires their peptidyl-
prolyl isomerase (PPIase) activity that accelerates protein folding/
unfolding [17]. Most cyclophilins also bind the immunosuppres-
sive drug cyclosporin-A (CsA) [18]. In humans, the resulting het-
ero-dimeric complex inhibits calcineurin, blocking the signal
transduction pathway to interleukin production [19,20]. Human
cyclophilins have also recently become interesting drug targets
in a number of diseases including HIV [21,22] and HCV infection
[23–27], malaria [28,29], ischemia [30–32], immunosuppression,
as well as showing potent anti-nematode effects [16,33,34].
PNCA, an ubiquitous eukaryotic protein, is essential for DNA
replication, DNA repair and plays major roles in the post-replica-
tive processing of DNA [35,36]. Functional PCNA is a toroidal trimer
capable of encircling double-stranded DNA, enhancing polymerase
processivity by tethering the polymerase complex to the target
DNA [37,38]. Many of the proteins that interact directly with PCNA
are involved in the mechanics of DNA replication and repair
[37,38]. PCNA also interacts with proteins involved in post-replica-
tive processing and with cell cycle regulatory proteins such as
Gadd45 and p21 (WAF1/Cip1) [35,39,40]. As a result of its central
role in DNA replication and repair, PCNA has been highlighted
[41] as a potential therapeutic target in a multitude of proliferative
cancers.
Our laboratory has previously found that his-tags have adversely
affected both the structure and function of cyclophilins and PCNA in1 Abbreviations used: hCypA, human cyclophilin-A; hPCNA, human proliferating cel
nuclear antigen; PPIase, peptidyl-prolyl isomerase; CsA, cyclosporin-A; IEX, ion-
exchange; GF, gel-ﬁltration.la variety of activity and structural assays, as well as in a number of
small molecule screening assays. In addition, tag cleavage has
proved less than straightforward, for reasons undeﬁned, and many
of our small molecule screening assays and structural analyses
require production of milligram amounts of very pure and active
protein on a regular basis. As a direct result, we developed reliable
and robust automated puriﬁcation protocols, for the production of
milligram amounts of very pure untagged recombinant human
CypA, by easily adapting an existing protocol [42], and for untagged
human PCNA, by development of a novel 4-step protocol, using the
ÄKTAxpress™ liquid chromatography system. Both automated pro-
tocols use generic commercially available pre-packed columns and
automatically prepared minimal buffers, essentially eliminating
user and system variations. They also maximize the run reproduc-
ibility and standardize the yield and purity between batches, in-
crease throughput and reduce user input to a minimum. The
automated 4-step protocol for hPCNA saves 4 working days over
the traditional method, greatly increasing the overall productivity
of the protocol. These two protocols further highlight the versatility
of the ÄKTAxpress™ liquid chromatography as a way of standardiz-
ing lab-scale/process protein production.Materials and methods
Materials
All chemicals used were of the highest grade available
commercially.
Plasmid construction
Expression plasmids for recombinant hCypA (pSW3-001) and
hPCNA (pT7-PCNA) were constructed as described [42] and [43],
respectively. pT7-PCNAwas kindly provided by Dr. EmmaWarbrick
(University of Dundee, UK).
Protein expression and puriﬁcation
All puriﬁcation was performed on ÄKTAxpress™ and ÄKTA-
Puriﬁer 100 UPC (GE Healthcare) equipment at 6 C. The ÄKTAx-
press™ instruments were used in a standard conﬁguration with
10 ml collection loops. HiPrep 26/60 S-200 HR gel-ﬁltration and Hi-
Prep 26/20 Desalt columns (GE Healthcare) were attached to the
system with the recommended lengths of 1.0 mm i.d. Tefzel

tub-
ing. All buffers, with the exception of Buffer-H, were generated on
an ÄKTA-Puriﬁer 100 system ﬁtted with an on-line Buffer Prep
function, a 2 ml mixing chamber, using a ﬂow rate of 30 ml min1
and the standard buffer recipes (Table 1) supplied with the instru-
ment software (UNICORN v 5.11, GE Healthcare). Proteins were de-
tected by absorbance at 280 nm. Culture volumes used were 1L in
all cases.
Traditional puriﬁcation of hCypA
The following protocol was adapted from the method described
by Wear et al. [42] to run with the appropriate pre-packed column
types for the ÄKTAxpress™ instrument and a minimal buffer
system. Recombinant hCypA was expressed and puriﬁed to homo-
geneity from OverExpress C41 BL21(DE3) Escherichia coli (Lucigen)
transformed with the pSW3-001 plasmid, grown shaking (260 rpm)
at 37 C for 16 h in Overnight Express Instant TB Medium (Nova-
gen) containing carbenicillin (100 lg ml1). Cells were harvested
by centrifugation and resuspended at 10% (w/v) in ice-cold Buf-
fer-A (Table 1), plus protease inhibitors. Lysis was performed at
6 C by a single passage through a Constant Systems Cell Disruptor
Table 1
List of buffers, composition and recipes used for chromatography steps.
Buffer Buffer composition Buffer stock solutionsa
Buffer-A 24 mM HEPES, pH 6.8 Line A1 – 100 mM HEPES
Line A2 – 100 mM NaOH
Line B1 – ddH2O
Line B2 – 2 M NaCl
Buffer-B 24 mM HEPES; 1 M NaCl,
pH 6.8
Line A1 – 100 mM HEPES
Line A2 – 100 mM NaOH
Line B1 – ddH2O
Line B2 – 2 M NaCl
Buffer-C 7.8 mM Na2HPO4;
150 mM NaCl, pH 7.5;
Line A1 – 30 mM Na2HPO4
Line A2 – 100 mM HCl
Line B1 – ddH2O
Line B2 – 2 M NaCl
Buffer-D 15.5 mM 1-methyl-piperazine;
15.5 mM Bis–Tris; 7.8 mM Tris,
pH 8.5
Line A1 – 50 mM 1-
methyl-piperazine; 50 mM
Bis–Tris; 25 mM Tris
Line A2 – 100 mM HCl
Line B1 – ddH2O
Line B2 – 2 M NaCl
Buffer-E 15.5 mM 1-methyl-piperazine;
15.5 mM Bis–Tris; 7.8 mM Tris;
1 M NaCl, pH 8.5
Line A1 – 50 mM 1-
methyl-piperazine; 50 mM
Bis–Tris; 25 mM Tris
Line A2 – 100 mM HCl
Line B1 – ddH2O
Line B2 – 2 M NaCl
Buffer-F 5.1 mM Na2HPO4; 5.1 mM
Formate Na; 10.2 mM Acetate
Na, pH 5.5
Line A1 – 30 mM
Na2HPO4; 30 mM Formate
Na; 60 mM Acetate Na
Line A2 – 100 mM HCl
Line B1 – ddH2O
Line B2 – 2 M NaCl
Buffer-G 5.1 mM Na2HPO4; 5.1 mM
Formate Na; 10.2 mM Acetate
Na; 1 M NaCl, pH 5.5
Line A1 – 30 mM
Na2HPO4; 30 mM Formate
Na; 60 mM Acetate Na
Line A2 – 100 mM HCl
Line B1 – ddH2O
Line B2 – 2 M NaCl
Buffer-H 25 mM Tris; 25 mM NaCl;
0.5 mM EDTA, 10% glycerol,
pH 7.5
Manually prepared
a Buffer recipe stock solutions and the ratio mixtures for the ﬁnal buffer com-
position were generated as described in the UNICORN (v5.11, GE Healthcare)
operating software.
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removed by centrifugation at 50,000g for 1 h at 4 C, and the ﬁl-
tered (0.22 lm) supernatant was then applied to a 5 ml HiTrap
SP HP column (GE Healthcare) pre-equilibrated in Buffer-A, at
4 ml min1. The resin was washed with 10 column volumes of Buf-
fer-A at a ﬂow rate of 4 ml min1 and bound proteins were eluted
with a gradient from 0% to 40% Buffer-B over 10 column volumes
(Table 1) at 4 ml min1, collecting 2 ml fractions. Relevant fractions
(hCypA elutes between 13% and 22% Buffer-B) were analysed using
SDS–PAGE (4–20% acrylamide), pooled (between 14% and 22%
Buffer-B) and the 10 ml sample ﬂushed from a 10 ml loop with
one loop volume plus an additional 3 ml onto a HiPrep 26/60 S-
200 HR gel-ﬁltration column (Vt  320 ml) (GE Healthcare) pre-
equilibrated in Buffer-C (Table 1). The column was run at
1.6 ml min1 and fraction collection was set to start after 0.6 col-
umn volumes and continue for a further 0.2 column volumes, col-
lecting 2 ml fractions. Fractions containing hCypA (hCypA peak
Ve = 223.2 ml) were pooled, concentrated to 500 lM and stored
on ice. hCypA wasP93% pure as judged by densitometric analysis
of SDS–polyacrylamide gels.Automated puriﬁcation of hCypA using ÄKTAXpress™
Recombinant hCypA was expressed and lysed as described
above. Buffer-A, Buffer-B and Buffer-C (Table 1) and default systemsettings for a 2-step ion-exchange (IEX), gel-ﬁltration (GF) proto-
col, in the cold, were used unless otherwise stated. Following lysis,
the clariﬁed supernatant was applied to an ÄKTAXpress™ system
ﬁtted with a 5 ml HiTrap SP HP column and a HiPrep 26/60 S-
200 HR gel-ﬁltration column. The IEX column was eluted with a
gradient from 0% to 40% Buffer-B over 10 column volumes. During
elution of the IEX column, collection was set to percentage, collect-
ing between 15% and 21% Buffer-B into a single loop. The peak
detection parameters were left as default for level and slope for
the GF step, run in Buffer-C at 1.6 ml min1, and fraction collection
was set to start after 0.6 column volumes and continue for a fur-
ther 0.2 column volumes, collecting 2 ml fractions. Invariably, frac-
tions A7–B1 of the hCypA peak were pooled, concentrated to
500 lM and stored on ice. hCypA was P93% pure as judged by
densitometric analysis of SDS–polyacrylamide gels.
Traditional puriﬁcation of hPCNA
OverExpress C43 BL21(DE3) E. coli (Lucigen) transformed with
the pT7-PCNA plasmid were grown shaking (250 rpm) at 37 C in
LB media containing carbenicillin (100 lg ml1) until the A600
was 0.7 and over-expression of recombinant hPCNA was induced
by addition of IPTG to 1 mM and growth for a further 3 h at 37 C.
Cells were harvested by centrifugation and resuspended at 10% (w/
v) in ice-cold Buffer-D (Table 1) plus protease inhibitors. Lysis was
performed at 6 C by a single passage through a Constant Systems
Cell Disruptor TS Series Benchtop instrument (Constant Systems)
set to 25 kPSI. Cellular debris was removed by centrifugation at
50,000g for 1 h at 4 C, and the supernatant applied to a 5 ml Hi-
Trap Q HP column (GE Healthcare) pre-equilibrated in Buffer-D,
at 5 ml min1. Following loading, the column was washed with
15 column volumes 27% Buffer-E (Table 1), followed by a 2.7 col-
umn volume gradient from 27% to 54% Buffer-E and then a 5 col-
umn volume gradient from 54% to 57% Buffer-E, at 5 ml min1.
Eluted protein was collected continuously in 1 ml fractions and
analysed using SDS–PAGE (4–20% acrylamide). Relevant fractions
were pooled from 50.7% to 55.5% Buffer-E. The protein pool
(17 ml) was split into two equal aliquots and loaded onto a Hi-
Prep 26/10 Desalting column (GE Healthcare) pre-equilibrated in
Buffer-F (Table 1), run at 8 ml min1 and collecting 1 ml fractions.
Relevant fractions containing protein were pooled and loaded onto
a 5 ml HiTrap Heparin HP column (GE Healthcare), pre-equili-
brated in Buffer-F, at 5 ml min1. Following loading, the resin was
washed with 5 column volumes of 18% Buffer-G (Table 1), followed
by an 8.2 column volume gradient from 18% to 100% Buffer-G, at
5 ml min1 collecting 2 ml fractions from 35.8% to 65.4% Buffer-G.
Eluted protein was analyzed by SDS–PAGE (4–20% acrylamide)
and relevant fractions pooled. The resulting 15 ml protein pool
was then split into two equal 7.5 ml aliquots and loaded (7.5 ml
sample ﬂushed from a 10 ml loop with one loop volume plus an
additional 3 ml) onto a HiPrep 26/60 Sephacryl S-200 HR gel-
ﬁltration column pre-equilibrated with Buffer-H (Table 1), at
1.6 ml min1. Relevant fractions containing hPCNA were analyzed
by SDS–PAGE, pooled from 110 to 128 ml, concentrated to
100 lM and stored on ice. hPCNA was P93% pure as judged by
densitometric analysis of SDS–polyacrylamide gels.
Automated puriﬁcation of hPCNA using ÄKTAXpress™
Recombinant hPCNA was expressed and lysed as described
above. Buffer-D, Buffer-E, Buffer-F, Buffer-G and Buffer-H (Table 1)
and default system settings for a 4-step ion-exchange (IEX), desalt
(DS), afﬁnity (AF), gel-ﬁltration (GF) protocol, in the cold, were
used unless otherwise stated. Following lysis, the clariﬁed super-
natant was applied to an ÄKTAXpress™ system ﬁtted with a 5 ml
HiTrap Q HP column, a HiPrep 26/10 Desalting column, a 5 ml
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tion column. Following loading, the 20 column volume wash-out-
unbound-material parameter was set to 0 and the column was
washed with 15 column volumes 27% Buffer-E, followed by a 2.7
column volume gradient from 27% to 54% Buffer-E and then a 5 col-
umn volume gradient from 54% to 57% Buffer-E, at 5 ml min1. Dur-
ing elution of the IEX column, collection was set to percentage,
starting at 50.6% Buffer-E collecting 10 ml into a single loop. During
elution of the DS column with Buffer-F, peak detection parameters
were set to start at 80 mAU, with a slope factor of 10 mAUmin1, a
peak max of 0.15 and peak end of 50 mAU, with collection into two
10 ml loops. The contents of both loops were loaded onto the AF
column with a peak-injection-ﬂush-volume of 20 ml Buffer-F.
Following loading, the AF column was washed with 5 column vol-
umes of 18% Buffer-G, followed by an 8.2 column volume gradient
from 18% to 100% Buffer-G. During elution of the AF column with
Buffer-G, collection was set to percentage, starting at 39.7%
Buffer-G collecting 10 ml into a single loop. The contents of the
AF loop were loaded onto the GF column with a peak-injection-
ﬂush-volume of 13 ml. During elution, peak detection parameters
were left as default for level and slope, with collection set to start
after 0.26 column volumes and continue for a further 0.21 CV, col-
lecting 2 and 1 ml fractions. Invariably, fractions A7–C11 of the
hPCNA peak were pooled, concentrated to 100 lM and stored
on ice. hPCNA wasP87% pure as judged by densitometric analysis
of SDS–polyacrylamide gels.
Peptidyl-prolyl isomerase (PPIase) assay
This colorimetric assay, performed essentially as described
[44,45], determines the rate of the cis to trans conversion of the
peptidyl-prolyl amide bond in the substrate N-succinyl-Ala-Ala-
Pro-Phe-p-nitroanilide (sAAPF-pNA). Selective enzymatic hydroly-
sis of sAAtransPF-pNA by a-chymotrypsin [46] releases p-ntitroan-
iline (pNA), the accumulation of which is monitored by the
absorbance at 400 nm. sAAPF-pNA, dissolved in 470 mM LiCl in
2,2,2-triﬂuroethanol (TFE) at 200 mM, was diluted to 4 mM in
LiCl/TFE immediately before use. Reactions were conducted at
6 C in 50 mM HEPES, pH 8.0, 100 mM NaCl; 5 mM DTT, in a total
reaction volume of 1 ml, essentially as described [44,45]. Final con-
centrations of hCypA and AAPF-pNA were 15 and 100 lM, respec-
tively. The initial linear portion of the slopes (0–1.2 s) were
converted to rates in lM s1 using the absorbance at 400 nm and
the extinction coefﬁcient e400 nm = 10,050 M1cm1. The IC50 was
determined by a least squares ﬁt of Eq. (1) to plots of the initial
reaction rate (background thermal isomerisation rate subtracted),
Vo (in lM s1), versus the concentration of CsA.
Vo ¼ V1 þ ðVzero  V1Þ=fð1þ ð½CsA=IC50ÞSlopeÞg ð1Þ
V1 is the reaction rate at inﬁnite inhibitor concentration (ﬁxed at 0),
Vzero is the initial velocity in the absence of inhibitor, [CsA] is the
concentration of CsA, IC50 is the concentration of CypA that causes
50% inhibition and Slope is the Hill number. Correction for substrate
competition was performed using Eq. (2).
Kds ¼ IC50=1þ ð½AAPF=KmÞ ð2Þ
[AAPF] is the initial AAcisPF-pNA concentration (mean = 51.6 lM)
and Km is the substrate Michaelis–Menten constant (798 ± 69 lM).
Miscellaneous
SDS–PAGE was performed as described [47]. The molecular
weights of hCypA, hPCNA and CsA are 18,012, 28,769 and
1202.12 Da, respectively. Protein concentration was determined
by measurement of absorbance at 280 nm and calculated usingthe extinction coefﬁcient 8490 M1 cm1, for hCypA and
16,305 M1 cm1, for hPCNA, or by BCA protein assay (Pierce) with
bovine serum albumin (BSA) as a standard.Results and discussion
hCypA
Although the 2-step protocol (cation exchange and gel-ﬁltra-
tion) for the puriﬁcation of untagged recombinant human CypA
(see Fig. 1A for typical soluble expression levels of hCypA) de-
scribed by Wear et al. [42] generates very pure and active protein,
there is still signiﬁcant manual intervention involved in processing
the samples through to purity. We streamlined the original [42]
traditional protocol (see Materials and methods for details) by
introducing several signiﬁcant improvements. This was achieved
primarily by using generic pre-packed columns, a set of automati-
cally generated minimal buffers (Buffer-A, Buffer-B and Buffer-C; Ta-
ble 1), containing only buffer salt and NaCl, eliminating the need
for any additional components (except for the addition of a prote-
ase inhibitor cocktail, added to the cell suspension mix just prior to
high-pressure lysis), and a signiﬁcantly increased ﬂow rate com-
pared to the previous method (4 and 1 ml min1, respectively)
[42]. We switched the cation exchange column of the ﬁrst step
to a generic commercially available column type (a 5 ml HiTrap
SP HP column; GE Healthcare), with a greatly reduced bed volume
(5 ml compared to the previous 50 ml). This, coupled with the in-
creased ﬂow rate, reduced the run time to less than 15% of the pre-
vious protocol (40 min compared to 300 min) [42]. The loss of
bed volume had no adverse effect on the amount of sample we typ-
ically needed to process and the elution peak of hCypA was, in gen-
eral, between 7 and 8 ml in volume. Cell extract from up to 3 l of
original E. coli culture could be similarly processed without any
apparent loss of purity or saturation of the dynamic binding capac-
ity of the column (40–60 mg protein ml1 of wet resin).hCypA
invariably eluted between 13% and 22% Buffer-B and, following
SDS–PAGE analysis, fractions collected between 14% and 22% Buf-
fer-B were pooled and processed over a HiPrep 26/60 S-200 HR
gel-ﬁltration column (GE Healthcare), loading with a 10 ml loop
with an additional 3 ml ﬂush volume and run in Buffer-C (Table
1). hCypA invariably eluted as a symmetrical peak with an elution
volume of 223.2 ± 0.3 ml (mean ± SD, n = 4). The streamlined tradi-
tional methodology was extremely reproducible; Fig. 1C illustrates
the ﬁnal protein obtained from 4 independent repeat runs. It rou-
tinely produced hCypA with a ﬁnal purity of P93% and ﬁnal yield
of 5 mg per litre of original bacterial culture (Table 2, Fig. 1C). The
yields and purity we obtained with this method were similar to
those obtained using the previous method [42]. However, the
batch purity and yield variability was signiﬁcantly reduced and
the total processing time (from cell pellet to pure protein) was re-
duced by at least half.
We next took the streamlined traditional protocol and trans-
lated it onto an ÄKTAXpress™ system ﬁtted with a 5 ml HiTrap SP
HP column and an HiPrep 26/60 S-200 HR gel-ﬁltration column,
with only a few minor changes to the run parameters previously
optimized for the traditional methodology. Recombinant hCypA
was expressed (Fig. 1A) and lysed identically to the traditional
method. Buffer-A, Buffer-B and Buffer-C (generated automatically;
Table 1) and default system settings for a 2-step ion-exchange,
gel-ﬁltration protocol, in the cold, were used except for the follow-
ing changes. The ion-exchange column was eluted with a gradient
from 0% to 40% Buffer-B over 10 column volumes, with collection
set to percentage, collecting between 15% and 21% Buffer-B into a
single loop. This sample was then processed onto the gel-ﬁltration
column run in Buffer-C. Fraction collection was set to start after 0.6
Fig. 1. Automated puriﬁcation of hCypA. (A) SDS–polyacrylamide gel (4–20% gradient) illustrating the typical levels of soluble hCypA over-expressed from OverExpress C41
BL21(DE3) E. coli grown for 16 h at 37 C in Overnight Express Instant TB Medium. hCypA makes up 6% of the total soluble protein. To, soluble cell extract at mid log phase
immediately after inoculation (A600 nm  0.5); T16, soluble cell extract following 16 h of growth shaking (260 rpm) at 37 C. (B) Typical chromatogram for the automated 2-
step puriﬁcation of hCypA using ÄKTAXpress™. The pre-packed columns used are illustrated above the corresponding section of the chromatogram; IEX – ion-exchange, GF –
gel-ﬁltration. Solid black; A280 nm in mAU (left axis). Solid red; NaCl gradient in % Buffer-B (right axis). The inset details the region of the gel-ﬁltration column elution from
which fractions were collected. Indicated fractions A7–B1 were pooled. (C) SDS–polyacrylamide gel (4–20% gradient) illustrating the ﬁnal purity levels of hCypA puriﬁed by
both traditional and automated protocols. Both methods produce protein of P93% purity (determined by gel densitometry). Five lg total protein was loaded in each lane.
Four independent traditional runs and 3 independent automatic runs are shown, illustrating the excellent reproducibility of both methods and the excellent comparable
purity between the methods. Molecular weight markers are shown to the right of the gel. (D) Inhibition of the PPIase activity (Vo in lM1 s1) of hCypA (15 nM) by
cyclosporin (CsA). hCypA puriﬁed by either the traditional or automatic method shows the same high speciﬁc activity. Open triangles, black line, automatically puriﬁed
hCypA; solid circles, red line, traditionally puriﬁed hCypA. The solid lines are a best ﬁt to Eq. (1) (see Materials and methods). The values for the equilibrium dissociation
constant for cyclosporin inhibition (Ki) are 24.3 ± 4.2 nM, for traditionally puriﬁed hCypA and, 19.7 ± 2.8 nM, for automatically puriﬁed hCypA, agreeing very well with
literature values [42,44,48]. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this paper.)
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collecting 2 ml fractions. Fig. 1B illustrates the typical chromato-
gram obtained from such an automated run. The inset shows the
detail of the hCypA peak; the elution volume for hCypA was
222.9 ± 0.12 ml (mean ± SD, n = 3), essentially identical to the
traditional method, and the fractions ﬁnally pooled from these runs
were invariably A7–B1 (Fig. 1B). Analysis of the ﬁnal pool of protein
indicated hCypAwasP93% pure (Fig. 1C), with independent repeat
runs of the automatic method producing protein with essentially
identical purity and yield (Fig. 1C, Table 2), illustrating the excellent
reproducibility of the automated protocol. Furthermore, the spe-
ciﬁc activity of puriﬁed hCypA is very high; Fig. 1D shows a compar-
ison of the PPIase activity of protein puriﬁed either by the
traditional method or the automated methods. The values for the
equilibrium dissociation constant for CsA inhibition (Ki) are
24.3 ± 4.2 nM, for traditionally puriﬁed hCypA, and 19.7 ± 2.8 nM,
for automatically puriﬁed hCypA, agreeing very well with literature
values [42,44,48].
Due to the ability to pool more judiciously andmanually process
the sample between columns with the traditional method, the ﬁnalyields of hCypA generated were typically 5–7% higher than the
automated method; yields were 5 mg per litre of original culture
(Table 2). However, the automated 2-step puriﬁcation protocol in-
volves very much less user intervention and the processing time
from cell pellet to ﬁnal pure protein is less than 12 h, including all
primary sample processing and column equilibration steps. This
saves almost half a working day of user intervention over the tradi-
tional method making the automatic method far more efﬁcient.
Despite this small loss of yield compared to the traditional protocol,
our automated puriﬁcation protocol for untagged recombinant
hCypA using the ÄKTAXpress™ system represents a very rapid, ro-
bust, reproducible and, most importantly, an improved generic
methodology for the production of milligram quantities of very
pure protein.
hPCNA
Novel protocols for the puriﬁcation of recombinant untagged
hPCNA from E. coli were developed from scratch (see Materials
and Methods for full details). We ﬁrst developed a traditional
Table 2
Puriﬁcation of hPCNA and hCypA. Fractionation was performed on cell pellets
obtained from 1 l of E. coli culture.
Fraction Total protein (mg)a Purity (%)b
hCypA – Traditional
Supernatant 498 6
Pooled SP HP fractions 5.8 88
Pooled S-200 fractions 5.2 P93
hCypA – Automated
Pooled S-200 fractions. 4.9 P93
hPCNA – Traditional
Supernatant 630 11
Pooled Q HP fractions 71.4 32
Pooled Heparin HP fractions 12.7 89
Pooled S-200 fractions 2.5 P93
hPCNA – Automated
Pooled S-200 fractions 3.6 P87
a Mean values from at least 2 individual repeat runs of the corresponding pro-
tocol. Protein concentration in the supernatant and the pooled fractions after each
chromatographic step was determined by BCA protein assay, apart from the ﬁnal S-
200 pool where protein concentration was determined by A280 measurements.
b Determined by densitometry of appropriate lanes on reducing SDS–polyacryl-
amide gels (4–20% gradient).
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(GF) methodology, again utilizing generic pre-packed columns
(suitable for use on the ÄKTAXpress™ system), and a set of auto-
matically generated minimal buffers (Buffer-D, Buffer-E, Buffer-F,
Buffer-G, Table 1; Fig. 2). The IEX column elution uses a relatively
complex 4-step gradient proﬁle: a wash immediately following
sample application with 15 column volumes of 27% Buffer-E,
followed by a 2.7 column volume gradient from 27% to 54%
Buffer-E, followed by a 5 column volume gradient from 54% to
57% Buffer-E, followed by a step to 100% Buffer-E. Relevant hPCNA
fractions from 50.7% to 55.5% Buffer-Ewere pooled and further pro-
cessed. This gradient proﬁle proved critical for ensuring hPCNA
eluted with as narrow an elution peak as possible (between 16
and 17 ml), while at the same time limiting the level and number
of contaminants, allowing an easy 2-repeat run processing through
the subsequent desalting step without further concentration.
hPCNA puriﬁed by this method was P93% pure as judged by den-
sitometric analysis of SDS–polyacrylamide gels (Fig. 2B) and typi-
cally yielded 2.5 mg per litre of original bacterial culture (Table
2). Despite the fact that very pure protein could be reproducibly
obtained (Fig. 2B), the traditional method requires a very consider-
able amount of manual intervention and typically takes 5 full
working days to process the protein from cell pellet through to
purity. Furthermore, a signiﬁcant amount of protein (1–2 mg)
was lost over the course of puriﬁcation due to a time-dependent
aggregation and resulting precipitation problems. These effects
were only partially alleviated by the addition of glycerol to the
chromatography buffers. Thus, in an attempt to reduce the loss
of protein, to greatly reduce the amount of user input to a mini-
mum and to further standardize the puriﬁcation, we streamlined
this method further by translating it into a fully automated proto-
col on the ÄKTAXpress™ system.
Clariﬁed E. coli cell lysate containing recombinant hPCNA was
applied to an ÄKTAXpress™ system ﬁtted with a 5 ml HiTrap Q
HP column (GE Healthcare), a HiPrep 26/10 Desalting column
(GE Healthcare), a 5 ml HiTrap Heparin HP column (GE Healthcare)
and a HiPrep 26/60 S-200 HR gel-ﬁltration column (GE Healthcare).
Buffer-D, Buffer-E, Buffer-F, Buffer-G (generated automatically; Table
1) and Buffer-H (Table 1), and default system settings for a 4-step
ion-exchange, desalting, afﬁnity, gel-ﬁltration protocol, in the cold,
were used except for the following changes (see Materials and
methods for full details). Following loading, column was washed
with 15 column volumes 27% Buffer-E (setting the default wash-out-unbound-material parameter to 0), followed by a 2.7 column
volume gradient from 27% to 54% Buffer-E and then a 5 column vol-
ume gradient from 54% to 57% Buffer-E, followed by a step to 100%
Buffer-E at 5 ml min1 (Fig. 2A). During elution of the IEX column,
collection was set to percentage, starting at 50.6% Buffer-E, collect-
ing 10 ml (instead of the default 7.5 ml) into a single loop; the pro-
tein was further processed through a desalting step. During elution
of the DS columnwith Buffer-F, peak detection parameters were set
to start at 80 mAU, with a slope factor of 10 mAUmin1, a peak
max of 0.15 and peak end of 50 mAU, with collection into two
10 ml loops. The contents of both loops were loaded onto a 5 ml
Heparin AF columnwith a peak-injection-ﬂush-volume of 20 ml Buf-
fer-F. Following loading, the AF column was washed with 5 column
volumes of 18% Buffer-G, followed by elution with an 8.2 column
volume gradient from 18% to 100% Buffer-G. During elution of the
AF column with Buffer-G collection was set to percentage, starting
at 39.7% Buffer-G, collecting 10 ml, again into a single loop. We
found the minor loss of sample arising from using the entire loop
volume, due to laminar ﬂow where velocity increases as the center
of the tube is approached, was more than compensated by the in-
creased yield that resulted from collecting 10 ml of sample through
the core of the eluted protein peak for both the IEX and AF col-
umns. The contents of the entire AF loop were then loaded onto
the GF column with the default peak-injection-ﬂush-volume of
13 ml. During elution peak detection, parameters were left as de-
fault for level and slope with collection set to start after 0.26 col-
umn volumes and continue for a further for 0.21 CV, collecting 2
and 1 ml fractions (Fig. 2A). Fractions, invariably A7–C11, of the
hPCNA peak were pooled, concentrated to 100 lM and stored
on ice. hPCNA wasP87% pure as judged by densitometric analysis
of SDS–polyacrylamide gels (Fig. 2B, Table 2).
Independent repeat runs of the fully automated method pro-
duced protein with the same degree of high purity (Fig. 2B), illus-
trating the excellent reproducibility of the automated protocol.
Streamlining and translation of the puriﬁcation protocol onto an
ÄKTAXpress™ system reduces the processing time to a fraction of
that taken by the traditional method. The automated run takes less
than 24 h, including all primary processing and column equilibra-
tion steps, with minimal user input to process the sample through
from cell pellet to ﬁnal purity, compared to the 5 full working days
of the traditional methodology. This is particularly important;
hPCNA is prone to time-dependent aggregation and the automated
protocol limits the loss of protein to this effect. As a direct result, the
ﬁnal yield of protein from a litre of original culture obtained from
the automated method was typically 40% greater than the tradi-
tional method (3.6 mg versus 2.5 mg; Fig. 2B, Table 2), purely as a
result of being able to process and purify the protein very much
more quickly. Our automated puriﬁcation protocol for untagged re-
combinant hPCNA using the ÄKTAXpress™ system represents a no-
vel generic methodology for the production of milligram quantities
of pure protein.
Concluding remarks
We have developed reliable and robust automated puriﬁcation
protocols, for the production of milligram amounts of very pure
untagged recombinant human CypA, by easily adapting an existing
protocol [42], and for untagged human PCNA, by development of a
novel 4-step protocol, using the ÄKTAxpress™ liquid chromatogra-
phy system. Both automated protocols use generic commercially
available pre-packed columns and automatically prepared minimal
buffers (essentially eliminating user error and system variations),
helping to further maximize run reproducibility and standardize
the yield and purity between batches. They also increase through-
put and reduce user input to a minimum; the automated 4-step
protocol for hPCNA saves 4 working days over the traditional
Fig. 2. Automated Puriﬁcation of hPCNA. (A) Typical chromatogram for the automated 4-step puriﬁcation of hPCNA using ÄKTAXpress™. The pre-packed columns used are
illustrated above the corresponding section of the chromatogram; IEX – ion-exchange, DS – desalt, AF – afﬁnity, GF – gel-ﬁltration. Solid black; A280 nm in mAU (left axis). Solid
red; elution gradient in % Buffer-E or Buffer-G (right axis), IEX and AF step, respectively. The buffer pairs used are indicated above the appropriate portion of the
chromatogram. The inset details the region of the gel-ﬁltration column elution from which fractions were collected. Indicated fractions A7–C11 were pooled. (B) SDS–
polyacrylamide gel (4–20% gradient) illustrating the ﬁnal purity levels of hPCNA puriﬁed by both manual (P93%) and automated (P87%) protocols (determined by gel
densitometry). The ﬁnal purity from 2 independent traditional and 2 independent automatic runs are shown, illustrating the excellent reproducibility of both methods.
Five lg total protein was loaded in each lane. SCE, soluble cell extract; R1, run 1; R2, run 2. Molecular weight markers are shown to the right of the gel. (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of this paper.)
60 C. Ludwig et al. / Protein Expression and Puriﬁcation 71 (2010) 54–61method increasing the overall productivity of the protocol. These
two protocols also further highlight the versatility and high degree
of reproducibility of the ÄKTAxpress™ liquid chromatography sys-
tem as a lab-scale production system.
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